IRVING, Texas, Nov. 21, 2024 /PRNewswire/ -- Caris Life Sciences(Caris), a leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announces that Jeffrey Vacirca, MD, FACP, has joined the Caris Board of Directors, effective November 7, 2024.

"We are thrilled to welcome Jeff to our board," said David Dean Halbert, DSc (h.c.), Chairman, Founder and CEO of Caris. "His extensive leadership across cancer care delivery, therapeutic development and patient/legislative advocacy, as well as his entrepreneurial experience, will bring an invaluable perspective to our board of directors."

"Understanding disease at the molecular level is rapidly changing cancer care, and Caris is clearly a precision medicine innovator and market leader," said Dr. Vacirca. "Like Caris, I have always placed the highest priority on quality in order to best serve patients. I am excited to join the Caris Board of Directors and work more closely with Caris leaders who share this same commitment to improving patient outcomes."

Dr. Vacirca has led New York Cancer & Blood Specialists (NYCBS) as the CEO and Chairman of the Board since 2008. In addition to his role at NYCBS, Dr. Vacirca formed the Conquering Cancer PAC and co-founded OneOncology and Odonate Therapeutics. He is the medical director for Oncology Network Development at Mt. Sinai Health Network and served as medical director for Long Island Association for AIDS Care. He serves on multiple boards, including the New York Cancer Foundation, PatientPoint, Annexus Health, OneOncology and the Suffolk County Police Foundation.

Dr. Vacirca earned his medical school degree from St. George's University School of Medicine and completed his residency and fellowship at State University of New York in Stony Brook.

About Caris Life Sciences
Caris Life Sciences (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition, and we value our employees as much as we do our patients of every creed, color, sex, sexual orientation and religion. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com.

Caris Life Sciences Media:
Corporate Communications
[email protected]
214.294.5606

SOURCE Caris Life Sciences